<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04590287</url>
  </required_header>
  <id_info>
    <org_study_id>4/2020</org_study_id>
    <nct_id>NCT04590287</nct_id>
  </id_info>
  <brief_title>ICF in Secondary Prevention of Cardiovascular Disease</brief_title>
  <official_title>The Use of ICF Classification System in Secondary Prevention of Cardiovascular Disease Among Others Ischemic and Hemorrhagic Stroke.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poznan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poznan University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to develop a practical protocol based on the ICF(The International&#xD;
      Classification of Functioning, Disability, and Health) the risk factors of cardiovascular&#xD;
      disease (CVD) in secondary prevention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The original ICF assessment sheet contains CVD risk factor categories, such as comorbidities&#xD;
      (depressive disorders, insomnia, heart rhythm and heart rate disorders, carotid artery&#xD;
      disease, and hypertension), measures of liver and renal impairment, disorders of carbohydrate&#xD;
      and lipid metabolism). The evaluation criteria for each category were determined based on&#xD;
      recommendations defined in the ESC, AHA, EFSD, and KIDIGO guidelines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 15, 2020</start_date>
  <completion_date type="Actual">October 1, 2020</completion_date>
  <primary_completion_date type="Actual">October 1, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Weeks</target_duration>
  <primary_outcome>
    <measure>emotional functions</measure>
    <time_frame>first examination on admission</time_frame>
    <description>symptoms of depression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>sleep functions</measure>
    <time_frame>first examination on admission</time_frame>
    <description>symptoms of insomnia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>heart rate</measure>
    <time_frame>first examination on admission</time_frame>
    <description>heart rate per minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>heart rhythm</measure>
    <time_frame>first examination on admission</time_frame>
    <description>heart rhythm interpreting ECG (regular or irregular)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>functions of arteries</measure>
    <time_frame>first examination on admission</time_frame>
    <description>carotid stenosis [%]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>increased blood pressure</measure>
    <time_frame>first examination on admission</time_frame>
    <description>blood pressure value [mm/Hg]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>functions related to the coagulation of blood.</measure>
    <time_frame>first examination on admission</time_frame>
    <description>International Normalised Ratio (INR) testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycosylated hemoglobin</measure>
    <time_frame>first examination on admission</time_frame>
    <description>HbA1c [%]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>lipid metabolism.</measure>
    <time_frame>first examination on admission</time_frame>
    <description>LDL [mg/dL]</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Secondary Prevention</condition>
  <condition>Risk Factor, Cardiovascular</condition>
  <arm_group>
    <arm_group_label>Patients after ischemic stroke</arm_group_label>
    <description>The analysis included the presence of CVD risk factors in patients after ischemic stroke durning in the early rehabilitation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients after hemorrhagic stroke</arm_group_label>
    <description>The analysis included the presence of CVD risk factors in patients after hemorrhagic stroke durning in the early rehabilitation.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        60 patients after ischemic stroke 60 patients after hemorrhagic stroke&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  the first episode of ischemic stroke or hemorrhagic stroke,&#xD;
&#xD;
          -  full medical documentation with a description of the above-mentioned risk factors&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  another neurological disease: brain tumor, trauma craniocerebral&#xD;
&#xD;
          -  incomplete medical history - no data on assessed risk factors CVD&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ewa Chlebuś, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic Rehabilitation, University of Medical Sciences in Poznań</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Rehabilitation and Physiotherapy Rehabilitation,</name>
      <address>
        <city>Poznań</city>
        <zip>61-545</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 9, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 9, 2020</last_update_submitted>
  <last_update_submitted_qc>October 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

